Sectoral Asset Management Inc bought a new stake in Versartis, Inc. (NASDAQ:VSAR) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 104,757 shares of the biopharmaceutical company’s stock, valued at approximately $1,828,000. Sectoral Asset Management Inc owned approximately 0.29% of Versartis at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the stock. Perceptive Advisors LLC increased its holdings in Versartis by 6.1% during the first quarter. Perceptive Advisors LLC now owns 4,407,317 shares of the biopharmaceutical company’s stock worth $94,096,000 after buying an additional 253,632 shares during the last quarter. Driehaus Capital Management LLC bought a new stake in Versartis during the first quarter worth $4,117,000. Renaissance Technologies LLC raised its position in Versartis by 334.6% during the first quarter. Renaissance Technologies LLC now owns 214,700 shares of the biopharmaceutical company’s stock worth $4,584,000 after acquiring an additional 165,300 shares in the last quarter. Vanguard Group Inc. raised its position in Versartis by 11.9% during the second quarter. Vanguard Group Inc. now owns 1,121,401 shares of the biopharmaceutical company’s stock worth $19,569,000 after acquiring an additional 118,894 shares in the last quarter. Finally, TIAA CREF Investment Management LLC lifted its stake in Versartis by 63.1% in the second quarter. TIAA CREF Investment Management LLC now owns 288,960 shares of the biopharmaceutical company’s stock valued at $5,042,000 after acquiring an additional 111,824 shares during the last quarter. 78.24% of the stock is owned by institutional investors and hedge funds.

In other news, major shareholder Life Sciences Maste Perceptive sold 2,130,000 shares of the business’s stock in a transaction that occurred on Friday, September 22nd. The shares were sold at an average price of $3.29, for a total value of $7,007,700.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 10.90% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “104,757 Shares in Versartis, Inc. (VSAR) Acquired by Sectoral Asset Management Inc” was reported by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.watchlistnews.com/104757-shares-in-versartis-inc-vsar-acquired-by-sectoral-asset-management-inc/1603363.html.

Versartis, Inc. (NASDAQ VSAR) traded up 4.08% during midday trading on Monday, reaching $2.55. 1,197,862 shares of the company traded hands. The firm’s market capitalization is $90.72 million. Versartis, Inc. has a one year low of $2.40 and a one year high of $24.00. The firm has a 50-day moving average price of $18.37 and a 200-day moving average price of $18.36.

Versartis (NASDAQ:VSAR) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.20). Equities analysts predict that Versartis, Inc. will post ($3.61) EPS for the current fiscal year.

VSAR has been the subject of a number of analyst reports. Piper Jaffray Companies set a $26.00 price objective on shares of Versartis and gave the company a “buy” rating in a research report on Tuesday, June 27th. Zacks Investment Research raised Versartis from a “sell” rating to a “hold” rating in a report on Thursday, June 29th. BidaskClub downgraded shares of Versartis from a “buy” rating to a “hold” rating in a report on Sunday, July 16th. Cantor Fitzgerald set a $34.00 price objective on shares of Versartis and gave the company a “buy” rating in a research report on Thursday, July 27th. Finally, Canaccord Genuity set a $28.00 target price on shares of Versartis and gave the stock a “buy” rating in a research note on Friday, July 28th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $8.20.

About Versartis

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Want to see what other hedge funds are holding VSAR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Versartis, Inc. (NASDAQ:VSAR).

Institutional Ownership by Quarter for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.